CompletedNCT00771940Updated Feb 3, 2009

Peripheral Metabolic Effects of Ghrelin

A Phase 1 interventional study of Ghrelin in Healthy Controls, sponsored by University of Aarhus. Completed at 1 site in Denmark. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-02-03.

Sponsored by University of Aarhus · Phase 1, Interventional, and Basic science

Phase: Phase 1
Study type: Interventional
Enrollment: 8
Allocation: Randomized
Ages: 18 Years to 60 Years
Sex: Male

Study summary

The aim of this study is to investigate putative peripheral effects of ghrelin on glucose and lipid metabolism in healthy men. Eight subjects will be enrolled. The hypothesis is that ghrelin infusion causes insulin resistance and lipolysis.

Conditions studied

Healthy Controls

In context

Lead sponsor

University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 60 Years
Sexes eligible: Male
Accepts healthy volunteers: Yes

Inclusion criteria

BMI \< 27 kg/m2
Written informed consent
Non-smoker

Exclusion criteria

Exclusion Criteria:

Any disease including epilepsy
Any use of medications (excl. paracetamol)
Present or previous malignancy
Alcohol dependency
Allergy to any trial medication

Study design

Phase: Phase 1
Primary purpose: Basic science
Allocation: Randomized
Intervention model: Single group
Masking: Single (Participant)
Enrollment: 8 participants (estimated)

Study arms

Active comparator
Ghrelin
Drug: Ghrelin

Interventions

DrugGhrelin
Solvent, cont. infusion

What researchers measure

Primary outcomes

Plasma levels of glucose
Time frame: During study day

Secondary outcomes

Insulin signaling
Time frame: Study day
Serum levels of fatty acids
Time frame: Study day

Study locations

1 site

Aarhus University Hospital
Aarhus, Dk-8000, Denmark

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Feb 3, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00771940
Lead sponsor: University of Aarhus
First posted: Oct 15, 2008
Start date: Oct 2008
Primary completion: Jan 2009
Completion: Jan 2009
Last update: Feb 3, 2009

Study contacts

Jens Otto L. Jorgensen, MD

study director · Medical Department M, Aarhus University Horpital, Denmark

Esben T Vestergaard, PhD

principal investigator · Medical Department M, Aarhus University Hospital, Denmark

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University of Aarhus

Start the discussion